| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787645 | Journal of Thoracic Oncology | 2018 | 5 Pages |
Abstract
These in vitro data demonstrate that dacomitinib can directly induce T790M or C797S secondary mutations. Our data suggest the importance of analyzing these secondary mutations because appropriate selection of EGFR inhibitors could overcome acquired resistance to dacomitinib in a subset of lung cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yoshihisa MD, PhD, Toshio MD, Masaya MD, Takamasa MD, Masato MD, Yuichi MD, Shuta MD, Masaki MD, Kenji MD, PhD, Toshiki MD, PhD, Tetsuya MD, PhD,